Could the calorically restricted ketogenic diet be an     effective alternative or supportive therapy for breast cancer?

Mateusz Psurski 1Magdalena Milczarek 2Beata Filip-Psurska 2Joanna Wietrzyk 2Józef Oleksyszyn 1

1. Wroclaw University of Technology, Division of Medicinal Chemistry and Microbiology (PWR), Wybrzeże Wyspiańskiego 27, Wrocław 50-370, Poland
2. Polish Academy of Sciences, Institute of Immunology and Experimental Therapy (IITD), Rudolfa Weigla 12, Wrocław 53-114, Poland

Abstract

Cancer is a complex disease characterized by the loss of the cellular control over the proliferation, caused by the accumulation of genetic and epigenetic defects. Recent findings shows that one of the major alternations found in almost all cancer cells, is a shift in the cellular glucose metabolism. This phenomenon - high rate glycolysis under aerobic conditions is known as “The Warburg Effect” and it is closely related to high metastatic potential of tumors.
Ketogenic diet is a low carbohydrate diet aim to induce ketosis. At this state, liver is using fatty acids to form acetylo-CoA, which is converted into ketone bodies. Ketone bodies are transported to other tissues where they are reconverted to acetylo-CoA, which can by use directly in Krebs cycle. Many cancer cells lack the activity of succinyl-CoA-acetoacetate-CoA transferase and other enzymes needed in ketone bodies metabolism, thus this source of energy is unavailable for them. KetoCal®, ketogenic diet produced by Nutricia is  a nutritionally balanced soybean oil diet that was originally developed for managing refractory epilepsy in children. Recent studies showed that KetoCal®, given in restricted amounts reduces plasma glucose levels and elevates ketone bodies levels leading to significant decrease in the brain tumors growth. Additionally, it showed anti-inflammatory, anti-angiogenic and pro-apoptotic activity.
Our goal was to test the possibility of using ketogenic diet in other kinds of cancers. Moreover, we wanted to check the possible synergistic effects between diet and commonly used cytostatic – cyclophosphamide. In our experiment we used mouse breast cancer model  4T1 that closely resembles breast cancer in humans. Ketogenic diet was administered to Balb/c female mice in restricted amounts (1 gram per day per mouse). KetoCal ® (KD) alone and administered with cyclophosphamide (KD+CY) decreased growth of  tumors by about 35% and 80%, respectively, compared to the control group (C) which received standard fodder in unrestricted amounts. Ketogenic diet showed additive effect in inhibiting 4T1 growth when combine with cyclophosphamide.  Spleens from group KD+CY were significantly smaller in comparison with the control group. Metastasis in lungs were also significantly lower in KD and KD+CY groups. This results indicate that KetoCal® has anti-tumor and anti-metastatic effect in experimental mouse breast tumors when administered in restricted amounts. We can assume that ketogenic diet can be used in the treatment of the other cancers than brain tumors. Moreover, we showed that it could be use not only as an alternative therapeutic option, but also as an supportive therapy during standard chemothe- rapy.

Legal notice
  • Legal notice:

    Copyright (c) Pielaszek Research, all rights reserved.
    The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
    In every case, proper references including Author(s) name(s) and URL of this webpage: http://science24.com/paper/22967 must be provided.

 

Related papers
  1. Synthesis of new 5H-indolo[2,3-b]quinoline derivatives with a high selective cytotoxic activity
  2. Administration of isothiocyanate-derived mercapturic acids inhibits solid tumor growth of 4T1 murine mammary carcinoma cells in BALB/c mice
  3. Preliminary studies on application of library of artificial receptors for differentiation of metabolites in urine of healthy and cancer mice
  4. Starch derivatives as vehicles for drug delivery in anticancer therapy
  5. Mercapturic acids as a naturally occurring isothiocyanates prodrug form with site-directed delivery system built-in based on an oxidative environment of the tumor
  6. Synthesis and biological activity of novel N,N-cyclic-2,4-dihydroxythiobenzamide derivatives
  7. Anticancer activity of vitamin D, genistein and indoloquinoline analogs
  8. Synthesis and anticancer activity of acetylenic derivatives of betulin
  9. Interaction of endotoxin and polymyxin B in B16 mouse melanoma model of metatstasis
  10. Anticancer activity of the conjugates:  modified fibrinogen – methotrexate.
  11. Synthesis and cytotoxic activity of new Pt (II) complexes with nitropyrazoles in aerobic and hypoxic conditions
  12. Vitamin D analogs enhance the activity of imatinib mesylate in human non-small cell lung cancer model
  13. Colon cancer treatment with the use of vitamin D analogs and irinotecan 
  14. Novel bifunctional synthetic isothiocyanates with high antiproliferative activity
  15. Naturally occurring hydroxyalkyl isothiocyanates and isothiocyanatoalkyl benzoates - structure-activity and structure-mechanism of action relationship studies.
  16. Synthesis and biological evaluation of new amino acid and dipeptide derivatives of neocryptolepine as anticancer agents. 
  17. Antitumor activity of carrier-methotrexate conjugates.
  18. CLA derivatives as functional food compounds
  19. New acetylenic derivatives of betulin with anticancer activity
  20. Catalytic synthesis and antiproliferative activity in vitro of polisubstituted isoxazolopyridine derivatives.
  21. Steroid profile of Asplenium cuneifolium
  22. The influence of (24R)-1,24- dihydroxyvitamin D3 on the anticancer activity of 5-fluorouracil in human colon cancer model
  23. Comparison of antiproliferative activity of the natural isothiocyanates and their mercapturic derivatives.
  24. Analogs of genistein and its possible anti-metastatic properties
  25. The influence of novel analogs of vitamin D3 on the antiproliferative activity of cisplatin or doxorubicin on human promyelocytic leukaemia cell line HL-60 
  26. New amino acid and peptide derivatives of 5H-indolo[2,3-b]quinoline and their biological activity.
  27. The cytotoxic activity of glycosides of indolo[2,3-b]quinoline derivatives.
  28. Disubstituted indolo[2,3-b]quinoline derivatives - the cytotoxic activity in vitro against various human tumor cell lines.
  29. Mono substituted 5H- and 6H-indolo[2,3-b]quinoline derivatives and their ability to overcome the barrier of drug resistance.
  30. Synthesis and antiproliferative activity in vitro of (4-substituted-2-butynylthio)quinolines
  31. New calcipotriol analogs, their toxicity and antitumor activity in vivo in comparison to the affinity with VDR and DBP
  32. Synthesis and cytostatic activity of new 1-substituted 6H-pyrido[4,3-b]carbazole derivatives
  33. The new analogs of genistein decrease mitochondrial membrane potential and activate caspase-3
  34. New amino acid derivatives of 6H-indolo[2,3-b]quinolines
  35. Influence of Transformation of the Amino Group in Anthracyclines into -N=CH-N< or -N=CH-O- Group on Their Biological Properties
  36. PRIMARY CYTOTOXICITY EVALUATION OF NEW HETEROCYCLIC SYSTEMS WITH PYRIDODIAZEPINE.
  37. SYNTHESIS AND ANTIPROLIFERATIVE ACTIVITY IN VITRO OF NEW 2-AMINOBENZIMIDAZOLE DERIVATIVES. PART 3. REACTIONS OF 2-ARYLIDENE- AMINOBENZIMIDAZOLE WITH SELECTED 1,3-DIKETONES.
  38. CONJUGATED LINOLEIC ACIDS PREPARATIONS AS EFFECTIVE NUTRACEUTICS
  39. THE ANTIMETASTATIC EFFECT OF BACTERIOPHAGE T4* ADMINISTRATED IN COMBINED TREATMENT WITH SELECTED CYTOSTATICS IN MICE WITH B16 MELANOMA
  40. SYNTHESIS AND ANTIPROLIFERATIVE ACTIVITY OF DIACETYLENIC THIOQUINOLINES
  41. SYNTHESIS AND CYTOTOXIC ACTIVITY OF 10-DEACETYL-10-PROPARGILPACLITAXEL
  42. THE CYTOTOXIC GLYCOSIDES OF INDOLO[2,3-B]QUINOLINE DERIVATIVES. IN VITRO AND IN VIVO STUDIES
  43. MONO SUBSTITUTED 5H-INDOLO[2,3-B]- QUINOLINE DERIVATIVES AND THEIR ABILITY TO OVERCOME THE BARRIER OF DRUG RESISTANCE.
  44. DISUBSTITUTED INDOLO[2,3-b]QUINOLINE DERIVATIVES. THE CYTOTOXIC ACTIVITY IN VITRO AGAINST VARIOUS HUMAN TUMOR CELL LINE.
  45. ANTITUMOR EFFECT OF CISPLATIN OR FLUOROURACIL IN COMBINED TREATMENT WITH (24R)-1,24-DIHYDROXYVITA- MIN D3
  46. FIRST ROUND STUDIES ON LEWIS LUNG CARCINOMA ACTIVITY OF THE NEW LEAD STRUCTURES IN THE ISOXAZOLE HETEROCYCLIC SYSTEM
  47. GENISTEIN, ITS NEW ANALOGS AND COMPLEXES - THE ANTIPROLIFERATIVE EFFECTS ON HL-60 LEUKEMIA CELL LINE
  48. COMBINATION OF: IMATINIB, PRI-2191 AND CYTOSTATICS - THE ANTIPROLIFERATIVE EFFECTS ON HL-60 LEUKEMIA CELL LINE
  49. ANTIPROLIFERATIVE ACTIVITY IN VITRO OF DIASTEREOMERIC ANALOGUES OF VITAMIN D3 AGAINST NORMAL AND CANCER CELL LINES

Presentation: Poster at VII Multidyscyplinarna Konferencja Nauki o Leku, by Mateusz Psurski
See On-line Journal of VII Multidyscyplinarna Konferencja Nauki o Leku

Submitted: 2010-03-13 16:35
Revised:   2010-04-05 20:06
Google
 
Web science24.com
© 1998-2022 pielaszek research, all rights reserved Powered by the Conference Engine